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Extracorporeal Photochemotherapy (ECP) is a widely used immunotherapy for 
cutaneous T cell lymphoma, as well as an immunomodulatory treatment for graft versus host 
disease (GVHD) and rejection of allografts. We hypothesized that ECP’s physiologic induction of 
large-scale monocyte-to-dendritic antigen presenting cell (APC) conversion is mechanistically 
responsible for both its anti-cancer effect and its tolerogenic impact in the transplant setting. 
To interrogate this possibility in an experimental system, we developed an ECP device that is 
scalable from mouse to man and tested its capacity to produce APCs that, when 
advantageously tuned and tumor antigen-loaded, can limit the growth of otherwise lethal 
tumors in the engineered Yale University Mouse Melanoma (YUMM) 1.7 model (driven by PTEN 
loss, BRAFV600E activation and CDKN2A mutations). Untreated control mouse tumors (N=169) 
were 7 to 10-fold (p<0.001) larger than ECP treated (N=40) tumors at the termination point, as 
required due to control tumor size.  Depletion of ECP-induced APCs from the cellular vaccine 
preparation prevented the immunoprotective effect (p<0.01), indicating a primary role for ECP-
induced APCs. Depletion of platelets from the ECP-processed cellular suspension also prevented 
the immunizing effect (p<0.01), substantiating prior in vitro evidence that physiologic ECP-
induction of functional DC is signaled by transient monocyte adherence to platelets. Addition of 
8-MOP-UVA-treated PBMCs to the otherwise immunoprotective APC vaccine completely 
reversed the immunoprotective vaccine effect (p<0.01), revealing that maturationally truncated 
APCs are counterproductively tolerogenic. Collectively, these results show that, in ECP, platelet-
induced tumor-loaded mature APCs are immunotherapeutic for established murine melanoma, 
while immature APCs are tolerogenic. These findings verify a pivotal role for ECP-manufactured 
 
 
APCs and are the first in vivo study to suggest the intriguing possibility that ECP can be modified 
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Direct tumor cytotoxicity has been a major focus of anti-cancer therapies for much of 
the 20th century. However, with the recent clinical successes of immunotherapy, interest has 
grown in the therapeutic potential of fighting cancer with the body’s immune system (32-35).  
Traditional dendritic cell (DC) cancer vaccines, although promising, have failed to significantly 
improve clinical outcomes (36). Efforts to produce clinical remissions by cellular vaccination 
have been handicapped by two practical limitations:  use of antigen presenting DCs which are 
produced ex vivo under conditions which cannot be reproduced in vivo, thereby limiting their 
efficacy, and loading of these DCs with antigens not distinctive to the array of patient specific 
markers. However, one DC-based method, “Extracorporeal Photochemotherapy (ECP)”, 
developed by Dr. Richard Edelson, and now effectively used worldwide to treat advanced 
cutaneous T cell lymphoma (CTCL), offers potentially valuable advantages.  ECP’s mechanism 
was recently shown to centrally involve physiologically-induced DCs, efficiently loaded with 
apoptotic CTCL cells, whose antigens are then used to stimulate clinically potent CD8 anti-CTCL 
clinical responses.  Hence, it is now possible to examine whether ECP can be a treatment for 
other cancers, including solid tumors. 
 
The ECP mechanism 
CTCL describes a group of non-Hodgkin’s lymphoma malignancies, characterized by skin lesions 
caused by infiltrating malignant T cells (23).  Prior to the introduction of ECP, CTCL was almost 
universally fatal. ECP treatment for CTCL was established in 1987 with a groundbreaking phase I 
clinical study in the New England Journal of Medicine by Edelson and colleagues.  They reported 
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that 27 of 37 (73%) CTCL treatment resistant patients receiving ECP responded with greater 
than 25% clearing of skin. Of the responding patients, 33% had greater than 75% skin clearance. 
All treated patients had no significant side-effects (12). Within a year, it was the first FDA 
approval of its kind, and far ahead of its time. It would be two decades before another cellular 
anti-cancer immunotherapy was approved (12, 10). 
  ECP is a systemic therapy that sequentially involves the separation of leukocytes from 
whole blood, routing of leukocytes through a chamber with exposure to photochemotherapy 
via 8-methoxypsoralen (8-MOP or psoralen) and ultraviolet A (UV-a) light, and return of all 
blood components to the patient. Psoralen irreversibly forms covalent bonds with DNA (ie., 
photoadducts) in the presence of UV light, inducing cytotoxic DNA damage to exposed cells 
(23). 
For much of the time following its approval, the mechanism of ECP remained largely 
elusive. Initially, the effectiveness of the treatment was thought to be due to 
photochemotherapy-induced T cell cytotoxicity. However, subsequent studies by Edelson and 
colleagues showed that only 10% of circulating malignant T cells are exposed to the 
psoralen/UVA (PUVA) treatment, which lead them to postulate that the anti-tumor response 
was immune mediated (10). Additionally, ECP was later shown to produce immunosuppressive 
responses in graft vs host disease (GVHD) patients. These paradoxical effects of immune 
activation and suppression in different patient populations clouded the mechanism further. 
Recently, however, several major elements of this mechanism have come to light: 1) ECP 
efficiently converts circulating blood monocytes into physiologic antigen presenting DCs; 2) 
PUVA creates immunogenic apoptotic malignant T cells which are processed and presented by 
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these DCs to initiate a CD8 anti-tumor response; 3) tolerance, in part, results from maturational 
truncation of monocytes following PUVA exposure (8, 10, 27). 
ECP-treated malignant cells can be immunogenic. Edelson and Berger performed 
experiments in the mid-90s that involved immunizing mice against an aggressive form of 
lymphoma (10, 15, 16).  They used 2B4.11 hybridoma cells that were the product of pigeon 
cytochrome C primed T lymphoblasts and BW5147 thymomas. The mice were injected with 
treated 2B4.11 cells two times per week for four weeks, then challenged with untreated 2B4.11 
malignant cells. All 10 of the control mice died within 4 weeks. Two of the 15 treated mice were 
dead by week 5, while those remaining were free of disease (10, 15,). To further increase the 
treatment efficacy, they loaded IL4-cultured DCs with PUVA-treated malignant cells followed by 
co-injection and subsequent challenge as before. All the control mice were dead within 41 days. 
Mice receiving treatment with DCs and PUVA treated 2B4.11 cells had improved survival, with 
the best group demonstrating “100% inhibition of tumor growth” (10, 16). Later studies 
established that PUVA-treated CTCL cells undergo apoptosis and enhance their MHC class I 
synthesis (3, 20, 10). These results indicated that PUVA-treated malignant cells are sufficiently 
antigenic. 
ECP passage manufactures physiologic DCs via monocyte-platelet interactions. Berger 
and Edelson also developed “table top” ECP using human PBMCs and found that the resulting 
monocytes began differentiating into DCs within the first 24 hours post-treatment (22, 17). 
Their first report showed that treated monocytes began to display a DC phenotype consisting of 
CD83 and CD36 expression in the absence of CD14 staining. These cells were phagocytic, 
capable of engulfing apoptotic malignant cells, and activating T cells in vitro (22). Subsequent 
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studies validated these findings, including a genome wide analysis showing that ECP-treated 
monocytes exhibited a gene expression pattern consistent with DC differentiation (17). 
Importantly, recent work has shed light on how ECP contributes to this DC differentiation. 
Durazzo et al. demonstrated that ECP induces monocytes to enter the DC differentiation 
pathway via their interactions with platelets during extracorporeal passage. They reported a 
process by which platelets adhere to the device chamber wall, become activated, engaging 
passing monocytes in a P selectin-dependent interaction that promotes DC differentiation in a 
manner dependent on platelet density and shear stress (8). 
Tolerance linked to DC maturational truncation. Given the capacity for ECP to produce 
both antigenic apoptotic malignant cells and functionally important APCs, it remained an open 
question how such events might explain its dual nature to both immunize and tolerize. Several 
reports had generally defined tolerogenic DCs as semi-mature (25), with low expression of co-
stimulatory molecules and increased production of immunosuppressive markers (26). Edelson 
and colleagues observed that during ECP, PUVA exposure was not uniform, instead conforming 
to a Gaussian distribution. This lead them to hypothesize that ECP might create two different 
subsets of DCs, one immunizing and the other tolerizing, all based on higher or lower exposure 
to PUVA.  Support for this hypothesis was demonstrated by Futterleib et al by showing PUVA 
exposure lead to an increasingly immunosuppressive DC phenotype. This included upregulation 
of the glucocorticoid-induced leucine zipper (GILZ) gene, a distinguishing marker of tolerogenic 
DCs. In addition, PUVA exposed DCs also down-regulated CD80 and CD86, gained resistance to 
toll-like receptor maturation, and increased IL-10 production (27). These data illustrated that 
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the immunosuppressive nature of ECP is tied to PUVA exposure leading to maturationally 
truncated tolerizing DCs.  
 
Expanding on ECPs success 
With foundational aspects of the ECP mechanism understood, the possibility emerged of 
utilizing that knowledge to potentially improve the therapy and test its activity in other cancers, 
specifically solid tumors. Given the role DCs were understood to have, the question became 
whether improving their capacity to present antigen would result in a more effective 
treatment. Girardi et al hypothesized that additional time for antigen processing and 
presentation following ECP might allow for improved immune activation and better clinical 
responses in patients. In a phase I trial, they demonstrated that the addition of an overnight 
incubation, allowing newly formed DCs additional time to process and present CTCL antigens, 
significantly improved the clinical responses of patients otherwise refractory to ECP (4, 20, 31). 
This modified version of ECP was termed Transimmunization. However, without additional in 
vivo pre-clinical data, there were limitations on what changes could be reasonably made to the 
clinical ECP protocol, which had remained largely unchanged since its FDA approval in the late 
1980s.  
In order to further improve upon ECP and test its potential against solid tumors, a 
tunable in vivo system was needed that could be used in mice for pre-clinical studies. As part of 
this goal, Edelson and collaborators from Transimmune AG developed a microplate inspired by 
the original ECP exposure chamber that was directly scalable from mouse to man. Preliminary 
studies between the two plates demonstrated comparable physical parameters (e.g, sheer 
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stress, cellular adherence), as well as the capacity to induce DC differentiation of human cells 
following passage (unpublished data). Additionally, the development of a transgenic 
(BRAFV600E/PTEN-/-) inducible melanoma system by Yale’s Marcus Bosenberg offered an ideal 
murine melanoma model to test (18). From an induced melanoma tumor, Bosenberg and 
colleagues generated a cell line (YUMM1.7) capable of being grafted into standard C57BL/6 
mice (28). This system afforded the opportunity to treat mice using antigens specific to their 
individual tumors, while conveniently utilizing the institutional expertise amassed by Dr. 
Bosenberg. 
With all the elements of a model system present, we endeavored to design a treatment 
protocol closely based on clinical ECP that was capable of answering a central question: Could a 
modified form of ECP be used as an effective immunotherapy against solid tumors?  Given the 
complex nature of the ECP mechanism and the possibility that additional elements might yet be 
undiscovered, our strategy was to make no assumptions about core elements of the procedure. 
Instead, our protocol was designed by working backwards from the known clinical ECP protocol, 
transferring as many of those elements as practically possible to the murine system. 
Here, we demonstrate enhanced antitumor activity via large-scale antigen presenting 
cell (APC) loading with apoptotic tumor cell antigens following murine ECP, termed 
Transimmune.  To our knowledge, this is the first report of an in vivo mouse treatment system 
that establishes a modified form of ECP as a potent immunotherapy against melanoma.  
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Statement of Purpose 
The purpose of this project was to determine if ECP-induced monocyte antigen 
presenting cells (APCs), armed with tumor antigens distinctive to the melanoma grafted in the 
same mouse, can generate an anti-tumor immune response.  
 
Specific Aims 
 Using ECP as a point of departure, develop a testable, reliable, and well tolerated mouse 
treatment protocol that approximates conditions typical of the common clinical 
situation.  
 Establish fundamental properties of a potential anti-tumor response including, if it is 
immune mediated and the nature of that immune response. 
 Compare characteristics of the antitumor response with known mechanistic principles 





MATHERIALS AND METHODS: 
Animals 
C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Age- and 
sex-matched mice that were at least 4 weeks of age were used for all experiments. All mice 
were used according to the labs Yale IACUC approved protocol and in accordance with the 
National Institutes of Animal Healthcare Guidelines. Murine melanoma xenografts: YUMM 1.7 
were injected subcutaneously at 1×105 cells per inoculum into the right flanks of recipient wild 
type C57BL/6 mice. Tumor formation and growth was assessed every 3 days until the 
experimental endpoint, at which point untreated mice were euthanized due to tumor volume, 
as per IACUC protocol. Tumor volume was monitored via biweekly measurement of 
perpendicular diameters and height using a caliper and tumor volume was calculated as abc/2. 
Relative tumor volumes were calculated based on the average tumor size of untreated mice on 
the last day of measurements being set at 100%. For example, if the average tumor size of PBS 
mice at the endpoint was 2000mm3 and TI mice averaged at 200mm3, then they were graphed 
as 100% and 10%, respectively. 
Tumors were harvested in their entirety at each experiments end (approximately 4 
weeks post inoculation) for histologic analysis. While the investigators assessing tumor growth 
were not blinded, all pathologists and laboratory personnel who performed histologic 
characterizations of tumor specimens were blinded to the group allocation. Sample sizes were 
chosen to ensure statistical power of detection based on projected outcomes. Differences in 





YUMM 1.7 is a melanoma cell line that is derived from C57BL/6 mouse melanoma with 
known genetic alterations (BrafV600E PTEN-/- p16-/- p19-/-).  Nomenclature for the lines is 
based from Yale University Mouse Melanoma (YUMM) followed by a number designating the 
genotype of the cell line.  
As follows, Katrina Meeth developed and isolated the YUMM1.7 cell line. Briefly, 
BRafCA, Tyr::CreER and Ptenlox4-5 mice were treated topically with 1-2 μl of 1.9mg/ml (5mM) 
4-HT at 6-8 weeks of age. Tumor growth was monitored with a digital caliper until the tumors 
ranged from 50mm3 to 100mm3. Melanoma cell lines were derived by physical resection of 
primary cutaneous tumors. Approximately, a 3 mm3 piece of Induced melanomas was 
dissociated by finely mincing with sterile scalpel in complete medium followed by collagenase 
digestion for 3 h and 0.025% trypsin/0.2 mmol/L EDTA for 30 min, triturated through a 20-
gauge syringe needle, and filtered by a 100μm nylon cell strainer (BD/Falcon, Bedford, MA) to 
yield a single-cell suspension. Cell suspensions were plated in media (a 1:1 mix of DMEM and 
Hams F12) supplemented with fetal calf serum (5%v/v) and penicillin, streptomycin and NEAA. 
Cells were cultured in DMEM F12 (Gibco, Carlsbad, CA) supplemented with 10% heat-
inactivated FCS, 1% of NEAA and 1% penicillin /streptomycin (Gibco) under standard conditions. 
And finally plated into DMEM:F12 with 5% FBS. Media was changed at the 12 hour time point. 





 The overall Transimmune procedure is listed below in parts. An overall schematic is 
available as Supplemental figure 5.  
 
Isolation of Murine PBMCs: 
Peripheral blood was collected from mice twice a week (Monday, Friday) for 3 weeks via 
non-lethal bleeding of the superficial temporal vein. The mouse was manually restrained with 
the lateral surface of the head facing the operator. Holding the purpose designed needle (18 
gauge) in the other hand, a stab incision is made into the cheek approximately halfway 
between the ear and the mandible with enough force to 
produce a small hole. Drops were collected into a 15ml tube prefilled with 0,2ml of 10% heparin 
per 10 mice. 
PBMCs were isolated from peripheral whole blood via Lympholyte gradient separation 
(LYMPHOLYTE®-M CELL SEPARATION MEDIA) via centrifugation at 2200 RPM for 20 min at RT 
with no break.  Cells underwent 2 washes in PBS followed by ACK buffer (Lonza) to eliminate 
the residual red blood cells. Lysis involved adding 300ul of ACK buffer to pelleted PBMCs, 
incubating on ice for 10min, followed by the addition of 700 ul PBS to wash.  
 
PUVA of YUMM1.7 tumor cells:  
To induce apoptosis of tumor cells, 2.5X106 YUMM1.7 cells were incubated with 100 
ng/ml  of 8-MOP  in 300ul of FBS for 20 minutes, and subsequently exposed to  4J/cm2 UVA 
light in a 12 well plate. Wells were pre-covered with cold FBS to reduce cell sticking. Coating 
FBS was removed just prior to the addition of YUMM1.7. Of note, titrating amounts of PUVA 
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dosages were performed in order to determine the minimum dosage to render YUMM1.7 
incapable of cellular division over a ten day long term culture. 
 
Pre-coating and Plate Passage via Microplate:  
Apoptotic YUMM1.7 tumor cells were combined with isolated murine PBMCS and 
contaminating platelets. In order to simulate the first five cycles of ECP (which do not utilize 
PUVA), we pre-coated the microplate with approximately two thirds (400ul) of the PBMC and 
YUMM mixture for 1hr. Presumably, this allowed for fibrin and platelet adherence to the walls 
of the microplate. Cells were then removed from the plate and recombined with the remaining 
1/3 of cells that remained in the tube at a final volume of 600ul. These cells were subsequently 
passed through the microplate to simulate ECP plate passage at a rate of 0.09 ml/min using a 
syringe pump. Of note, during passage, plate was rated at 45 degrees so that cells would “run 
uphill then downhill.” This was done to reduce bubbles and improve laminar flow. Following 
passage, cells were collected into an Eppendorf tube. The microplate was washed with 100% 
FBS at 0.49 ml/min while being physically perturbed by flicking the plate surface. This was done 
to help remove adherent cells from the plate during the wash step.  
 
Overnight Culture:   
To assess effect of an extended incubation period following m-ECP, cells were collected 
following plate passage and resuspended in RPMI with 15% mouse native serum and incubated 
overnight. This was identical to how patient samples were treated during the 
Transimmunization trial (4, 20, 31) The following day, cells were harvested, spun and 
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resuspended in native mouse serum and administered i.v. by retro-orbital vein to the mice. In 
early experiments, cell numbers were monitored however not controlled, since during the ECP 
procedure the number of cells a patient receives is not controlled either. On average, each 
mouse receives approximately 5x105 PBMC and YUMM each treatment. 
 
In vitro depletion 
CD11b depletion: Column-free magnetic separation was performed after the ACK buffer 
and before the incubation with the YUMM cells 1.7 using the EasySep mouse CD11b positive 
selection kit purchased from STEMCELL Technologies (Catalog # 18770). 
CD41 depletion: Column-free magnetic separation was performed after the ACK buffer and 
before the incubation with the YUMM cells 1.7 using CD41 Biotin and anti-Biotin MicroBeads 
purchased from Miltenyl Biotec (Catalog # 130¬105¬869, 130090485 respectively). 
 
Spleen adoptive transfer 
Treated and untreated mice were sacrificed within 1 week of their 6th and final 
treatment and splenocytes were collected. The spleen was homogenized by passing the tissue 
through a nylon mesh (70 µm) using a plunger. Red blood cells were removed using 
Lympholyte. Splenocytes were resuspended in PBS and injected via the retro-orbital plexus in 
naive five week old male C57bl6 mice. One donor spleen equivalent per recipient mouse was 
injected. In a second cohort we repeat the same experiment using CD3 isolated cells from the 
spleen. A tumor inoculum of 1x105 YUMM 1.7 was injected subcutaneously into the right flank 
on the same day as the spleen transfers. Tumor volumes were measured along 3 orthogonal 
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axes (a, b, and c) every 3 to 4 days and tumor volume was calculated as abc/2 every 3 days until 
the end of the experiment. 
 
In vivo antibody depletions 
Mice were injected i.p. on day 10 (approximate time of first treatment) with 
100ul/mouse of anti-NK1.1 (Biolegend), anti-CD8 (Biolegend), or with anti-CD4 (Biolegend) per 
the manufactures protocol. Injections were repeated biweekly for the duration of the 
experiment. 
 
Treating with PBMCs alone 
To determine the importance of YUMM as an antigen we removed the apoptotic 
YUMM1.7 from the treatment. Isolated murine PBMCS were subsequently passed the 
microplate.  Cells were collected following plate passage and resuspended in RPMI with 15% 
mouse native serum and incubated overnight. The following day, cells were harvested, spun 
and resuspended in native mouse serum and administered i.v. by retro-orbital vein to the mice. 
 
Treating with YUMM 1.7 Alone 
To assess the effect of YUMM alone we removed the PBMCs from the therapy. 2.5X106 
YUMM1.7 cells were incubated with 100 ng/ml of 8-MOP in 300ul of FBS for 20 minutes, and 
subsequently exposed to 4J/cm2 UVA light. Apoptotic YUMM was subsequently passed through 
the microplate.  Cells were collected following plate passage and resuspended in RPMI with 
15% mouse native serum and incubated overnight. The following day, cells were harvested, 
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spun and resuspended in native mouse serum and administered i.v. by retro-orbital vein to the 
mice. 
 
PKH phagocytic assay 
In order to determine the phagocytic potential of plate passaged monocytes, YUMM1.7 
cells were labeled with the membrane protein dye PKH-red (Sigma) per the manufactures 
instructions. Cells then underwent typical PUVA exposure and subsequent plate passage 
associated with Transimmune, or did not. PBMC and labeled YUMM were incubated overnight 
as outlined above. The next day, cells were harvested for FACS staining instead of being 
reinfused into recipient mice. For FACS, cells were washed and resuspended in FACS buffer, 
blocked with Fcy blocker for 5 min, and stained with fluorescently conjugated antibodies. Anti-
CD11b-pacblue (eBiosciences), anti-CD19-FITC (eBiosciences), and anti-MHCII-APC 
(eBiosciences) were used to identify potential phagocytes. PKH fluorescence was monitored via 
the PE channel. 
 
Cytokine Analysis 
Following the overnight incubation step of Transimmune, 100 ul of supernatant was 
harvested from individual culture dishes, centrifuged to remove contaminating cells, and stored 
at -20C for eventual cytokine analysis. Supernatants collected from 3-6 day cultures of purified 
monocytes and CD4 T cells from splenic transfer mice were also harvested and stored in this 
way. MHCII blocking was done using anti-MHCII I-A/I-E antibody (Biolegend) 1ug/well for the 
course of the 3 or 6 day incubation. Every other day, cells were pulsed with an additional 
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1ug/well.  For in vivo serum cytokine analysis, serum was isolated from treated or untreated 
mice 72 hours after each of the 6 treatments. Aliquots were stored prior to assaying as noted 
above. Supernatants or serum were thawed and sent to Yale’s Immune Monitoring Core Facility 
for Luminex testing. Samples were screened for the presence of 23 different cytokines or 
chemokines. They were as follows: IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40, 
IL12-p70, IL-13, IL-17, Eotaxin, G-CSF, GM-CSF, IFN-g, KC, MCP-1, MIP-1a, MIP-1b, RANTES, and 
TNF-a.  
 
Mouse Hematocrit and complete blood counts 
To monitor for anemia or signs of infection, 5 ul aliquots of heparinized blood collected 
on treatment days were set aside and sent to Yale’s Analytical Core facility for hematocrit and 
CBC testing. 
 
Splenic CD4 activation assay 
 In order to determine if there was evidence of CD4 activation associated with TI, 
recipients of spleen transfers from either TI or treated mice were sacrificed after their final 
measurements (approximately 30 days following tumor inoculations). Spleens from these mice 
were harvested as noted above. Additionally splenocytes were collected form mice not 
transferred any splenocytes originally (Ie, tumor bearing mice, termed PBS). CD11b+ and CD4+ 
T cells were negatively selected via STEMCELL isolation kits. These cells were plated overnight 
either alone or together for 3 or 6 days in RPMI based T cell media at 1x105 cells per well in a 96 
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well flat bottom dish. Supernatants from these cultures were collected and sent for Luminex 
cytokine analysis, as noted above. 
 
Note about performance of individual experiments 
The amount and breadth of work presented in this thesis would not have been possible 
without the significant contributions of others. In keeping with the spirit of science, this was a 
highly collaborative effort. This project itself was an equally shared joint project between 
Alessandra Ventura and me from the outset. The initial idea development, planning and 
experimental design for every experiment performed in this thesis was conducted together by 
myself and Alessandra Ventura. Initially, Transimmune experiments were performed by both of 
us at every level. However, after initial successes, we compartmentalized work to be more 
efficient, with Alessandra taking on the bleeding of mice, tumor inoculations, i.v. reinfusions, 
and tumor measurements. This amount of work cannot be understated. Every one of the 
hundreds of tumors in this thesis was injected and measured by Alessandra.  
In consultation with Ale, I took on the task of designing the treatment protocol so that it 
closely resembled the original ECP procedure. This was based on the original ECP papers 
describing minute details of the procedure, including the percentage of treated blood volume 
per patient, the estimated amount of treated cells, the volume ran over the ECP plate, the 
surface area of the original ECP plate, and the rate of flow through the chamber. Additional 
insights were gathered by observing several patients undergoing ECP, including how serum, 
white cells, blood cells layered onto the plate after each cycle. This all heavily informed the 
Transimmune treatment protocol design. For most of the in vivo experiments, I performed the 
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PBMC isolation, plate coating and passage, and overnight cultures. For later repeat experiments 
involving in vivo depletions, additional help was provided at various points in the TI protocol by 
Eve Robinson, who took on running plates if Ale or I were unavailable or needed additional 
assistance. 
Later in vitro studies, including PKH uptake assays, FACS, cytokine supernatant 
experiments were conducted by me, with assistance in mouse cell isolation provided by Ale 
and/or Eve. 
At every step of experimental planning, Ale and I benefitted greatly from insight and 
advice from Doug Hanlon, Eve Robinson, Katrina Meeth, Marcus Bosenberg, Robert Tigelaar 





Transimmune results in slower YUMM 1.7 tumor growth that is immunologically transferrable 
via splenocytes 
To test the therapeutic potential of an ECP-derived protocol against established solid 
tumors, we utilized the YUMM 1.7 murine melanoma xenograft system developed by Dr. 
Marcus Bosenberg. Preliminary titrations of increasing dosages of PUVA established 4 J/cm2 
and 100 ng/ml of 8-MOP as an effective kill dose for YUMM1.7 (data not shown). Two age and 
sex matched C57BL/6 mouse cohorts were compared, with the treatment arm receiving the 
Transimmune protocol, while the control group received phosphate-buffer-saline (PBS). Mice 
were inoculated on day 0 with YUMM 1.7 in the right flank. They received treatment twice a 
week for three weeks, with the first treatment commencing when tumors were palpable (7-11 
days post inoculation). Mice receiving Transimmune experienced a significant delay in tumor 
growth as compared to untreated mice (Fig. 1, Sup. Fig. 3). By the endpoint, at which untreated 
mice had to be euthanized due to tumor size, control tumors were >85% larger than 
Transimmune treated tumors (Fig. 1). Despite an expected transient anemia, mice generally 
tolerated the Transimmune treatment protocol with no significant complications (Sup. Fig. 2).  




C57BL/6 mice inoculated s.c. with 1E5 YUMM1.7 tumor cells were treated six times with Transimmune cells i.v. 
following an overnight incubation. Mean relative tumor volume growth plotted over time. Data is representative of 
seven independent experiments.  (***, p<0.001; ****, p<0.0001) 
To determine if the delay in tumor growth was immune mediated, splenocytes were 
transferred from either Transimmune or PBS mice following their final treatment into untreated 
tumor-bearing mice. An additional control group received PBS instead of splenocytes. Mice 
receiving whole splenocytes from Transimmune treated donors demonstrated a reduction in 
YUMM 1.7 tumor growth compared with controls (Fig. 2a). This pattern of growth was 
remarkably similar to mice directly receiving Transimmune treatment, indicating the effect was 
immune mediated and transferrable.  To further refine the subsets of immune cells responsible 
for the TI effect, transfers were repeated with splenocytes enriched for T cells by positively 
selecting out contaminating B cells and myeloid cells.  Mice receiving enriched T cell 
splenocytes maintained reduced tumor growth compared to those receiving no splenocytes or 
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those receiving T cells from untreated mice, indicating an important role for T cells in producing 
the Transimmune anti-tumor response. 
Figure 2. Transimmune effect is transferrable via splenocytes 
 
a,b,  C57BL/6  recipient mice were injected  on day 0 with one spleen equivalent of either whole splenocytes (a) or 
T-cell enriched splenocytes (b)  from untreated tumor-bearing mice  or Transimmune treated mice. Recipient mice 
were challenged with 1E5 YUMM1.7 cells immediately following splenocyte transfer. Mean relative tumor volume 
growth plotted vs time. 
Transimmune avoids problematic tolerance induction by avoiding PUVA treatment of normal 
PBMCs 
Given ECP’s history as an immunomodulatory therapy that can both immunize in CTCL 
and tolerize in GVHD, we hypothesized that Transimmune might share similar mechanistic 
principles traditionally associated with ECP. If true, these shared principles would aide in 
helping to further characterize the anti-YUMM1.7 effect associated with Transimmune. Since 
PUVA-induced maturational truncation of PBMC (specifically, monocytes) has been associated 
with tolerance induction via ECP, we hypothesized that the addition of PUVA treated PBMCs 
would prove tolerizing and therefore reduce the TI anti-tumor effect. This was tested by adding 
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an equal number of PUVA treated PBMC to TI cells prior to treatment, and comparing tumor 
growth in mice receiving standard TI treatment or PBS.  The addition of PUVA truncated PBMC 
resulted in complete loss of the TI anti-tumor response (Fig. 3), demonstrating the 
immunomodulatory potential of this treatment protocol to possibly both immunize and 
tolerize.  Additionally, by separating PUVA treatment of tumor cells from plate passage of 
PBMCs, Transimmune avoids the potential pitfall of tolerance associated with PBMC truncation. 
Figure 3. Addition of maturationally truncated PBMCs negates TI effect 
 
PUVA irradiated PBMC from C57BL/6  tumor bearing mice were mixed with Transimmune treated cells prior to 
being administered to recipient mice. Remaining protocol was unchanged from traditional Transimmune. Tumor 
growth over time was compared to mice receiving traditional Transimmune treatment or PBS. 
Plate passage and the presence of monocytes and platelets are required for both an in vitro 
proinflammatory cytokine profile and an in vivo anti-tumor response. 
 Monocytes have historically been shown to have an important role in clinical ECP, in 
part through platelet-induced activation during plate passage, leading to downstream tumor 
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antigen presentation and T cell activation. To determine whether a similar process was involved 
in Transimmune, we isolated supernatants from plate passaged cells following overnight 
incubation, and compared their cytokine profile with non-passaged cells and cells depleted of 
CD11b+ monocytes or CD41+ platelets prior to passage for signs of an inflammatory response. 
A Luminex panel of 23 cytokines was screened. Transimmune demonstrated a distinctive 
proinflammatory profile involving monocyte chemoattractant protein-1 (MCP-1), and IL-6 (Fig. 
4). In the absence of plate passage, monocytes, or platelets production of both cytokines was 
significantly diminished (Fig. 4). This indicates that Transimmune acutely induces a 
proinflammatory milieu in vitro that requires plate passage of monocytes with platelets. 
Interestingly, there was no evidence of Transimmune-specific cytokine production in the serum 
of treated mice (Sup. Fig. 4). To determine if plate passage and monocytes also play a role in 
the in vivo tumor response, mice were treated with Transimmune, un-passaged cells, or cells 
depleted of monocytes prior to passage. The anti-tumor effect of Transimmune was completely 
lost without plate passaged treatment cells, resulting in tumor growth matching that of 
untreated mice (Fig. 5a). Additionally, the removal of CD11b+ monocytes prior to plate passage 
also resulted in the complete loss of the TI effect (Fig. 5b). Consistent with known elements of 
ECP, these data illustrate the profound importance of plate passaged monocytes in the anti-
tumor response induced by Transimmune.  
Figure 4. Plate passage, monocytes and platelets are required for Transimmune-associated in 




Cytokine concentrations reported in pg/ml. Cytokines were collected from overnight supernatants containing 
passaged YUMM and PBMC following plate passage, no plate passage, or monocyte or platelet depletion prior to 
plate passage; *=p<0.05. 
 In order to determine how the process of plate passage might activate monocytes in 
Transimmune, we looked to ECP as a potential guide. It was previously shown that during ECP, 
passaged monocytes interacted with platelets anchored to the plate surface via adhesion 
molecules. These interactions proved crucial to subsequent monocyte activation and 
differentiation into immature DCs (8). We hypothesized that removal of platelets from cell 
mixtures prior to plate passage would reduce monocyte activation and thus the TI in vivo anti-
tumor response. Removal of platelets was accomplished through a positive selection CD41 
depletion kit following PBMC isolation but before plate passage. Mice were subsequently 
treated as described previously and compared to TI and PBS mice. Tumors in mice receiving 
platelet-depleted passaged cells grew at a rate similar to the PBS control mice (Fig. 5c). In 
addition to their role in producing proinflammatory cytokines (Fig. 4), these results highlight the 
important role platelets play in the Transimmune anti-tumor response, and are consistent with 
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previous reports implicating platelet-monocyte interactions as essential for downstream 
monocyte activation following ECP. 
 
Figure 5. Plate passage, monocytes and platelets are required for the Transimmune anti-tumor 
response 
 
a, In vivo tumor growth following treatment with cells that were not plate passaged, treated with TI, or mice 
receiving no treatment at all (PBS) . b, In vivo tumor growth following depletion of monocytes via positive selection 
of CD11b positive cells prior to plate passage. Tumor growth compared to TI or untreated cells. NS=not statistically 
significant.  c, Depletion of platelets via positive selection of CD41 positive cells prior to plate passage.  
YUMM are a necessary source of antigen and must be administered in the context of passaged 
PBMC in order to produce TI effect 
 Given the role activated monocytes play as APCs in ECP, we hypothesized a similar role 
in Transimmune. To show plate passaged monocytes as potential APCs, we first established 
their ability to take up PKH dye-labeled YUMM 1.7 debris (Sup. Fig 1). Next, to establish YUMM 
as an important source of antigen in vivo, mice were treated with passaged PBMCs alone that 
were not given a chance to be loaded with YUMM 1.7 debris. Tumor growth in these mice was 
no different than PBS mice, establishing YUMM as a necessary source of antigen for the TI 
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effect (Fig. 6). However, when mice were given PUVA-treated YUMM1.7 cells alone, it was not 
sufficient to reproduce the TI response (Fig. 6), indicating that YUMM antigen in the context of 
passaged PBMCs is essential for therapeutic efficacy. 
Figure 6. Passaged YUMM and PBMCs are necessary but insufficient alone for TI response 
 
YUMM or PBMC passaged separately, and administered separately. Tumor growth of each compared to TI and 
untreated mice. 
Recipient CD4, CD8, and NK cells are important in efferent arm of Transimmune anti-tumor 
response, and involve TI-specific IFNg production mediated through MHCII 
 In order to help decipher the efferent arm of Transimmune, mice were treated with TI 
while undergoing in vivo depletions of immune cell subsets. Antibodies against NK1.1, CD4, or 
CD8 were administered i.p. over the course of treatment, and tumor growth was compared 
with standard TI and PBS in non-depleted mice.  In vivo depletions of cells were confirmed via 
FACS peripheral blood analysis (data not shown). Tumor growth in mice depleted of CD8, CD4, 
and NK1.1 cells was no different than untreated controls (Fig. 7). Additional evidence of CD4 
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involvement came from long term (6 day) incubations of CD4+ T cells and CD11b+ monocytes 
isolated from recipient mice that had been transferred splenocytes from TI or untreated mice. 
Supernatants collected from these cultures demonstrated TI specific production of IFN-g when 
monocytes and CD4+ T cells were co-incubated (Fig. 7b). Low levels of IFNg were produced by 
mice receiving untreated splenocytes. (Fig. 7b). The addition of an anti-MHCII blocking antibody 
significantly inhibited the TI-specific IFNg production from co-incubated CD4+ T cells and 
monocytes (Fig. 7b). These data indicate a potential for a multifaceted effector TI response 
involving both innate and adaptive arms of the immune system, with CD4+ T cells activated via 
MHCII antigen presentation likely having a central role to play. 
Figure 7. CD4, CD8 and NK cells are central to the TI in vivo response that involves TI-specific 
IFNg production mediated through MHC Class II.  
 
a, in vivo depletions of CD4, CD8 or NK cells in recipient mice over the course of TI treatment. Tumor growth 
compared to TI and untreated mice. b, cytokine production following long term culture (3 and 6 days) of CD4 T cells 
and monocytes (CD11b+ cells)  in combination or separately. Additionally, cells in combination were blocked with 
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an anti-MHCII antibody. Cell collected from mice that received spleen transfers from TI or PBS mice. For 







ECP is widely used in clinical practice, inducing high response rates in patients with 
advanced CTCL. As a cellular immunotherapy, it activates monocytes to take up and process 
antigen from apoptotic cells through platelet dependent interactions. Its ability to produce 
potent APCs without suprapharmocologic concentrations of cytokines has made it particularly 
attractive as a potential cellular vaccination therapy. A central question for many ECP 
practitioners has been whether that potential could be realized in fighting solid tumors. (4, 29, 
31). Despite progress in understanding the mechanism of ECP, an in vivo pre-clinical system has 
not existed that would allow proper investigation of its potential to generate antitumor 
responses outside the realm of CTCL. Here, we establish a tunable, modified ECP melanoma 
system, scalable from mouse to man. To the best of our knowledge, this is the first known 
demonstration of an antitumor effect induced by modified ECP (Transimmune) in solid tumors, 
and has wide potential implications for the treatment of melanoma and other possible 
malignancies. 
 
A tunable system, optimal for treatment enhancement and gaining mechanistic insights 
 The Transimmune treatment protocol resulted in reliable slowing of YUMM1.7 
melanoma tumor growth, without significant complications or toxicities. The tunable nature of 
the TI system allowed several areas of the original ECP procedure to be modified in order to 
take advantage of the recent mechanistic insights by Edelson and others. First, we added an 
overnight incubation to the clinical procedure given the improvement in antigen uptake and 
processing demonstrated by the Transimmunization trial (31).  Consistent with their findings, 
29 
 
we found an improved antitumor response when the overnight incubation was added (data not 
shown). The overnight incubation also created the opportunity to assay cells (ie., phagocytosis, 
cytokines) following Transimmune before they were reinfused into mice, providing additional 
metrics to further characterize the response.  
Second, we compartmentalized PUVA treatment in order to avoid potentially creating 
maturationally truncated tolerizing DCs (27). Indeed, we established the capacity of PUVA to 
result in tolerizing APCs that were capable of mitigating a TI anti-tumor response. This was the 
first in vivo evidence to directly support the hypothesis that ECP’s induction of immunity and 
tolerance is linked with APC exposure to PUVA, as laid out by Futterleib and colleagues (27). 
This illustrates that limiting PUVA exposure to malignant cells and not APCs, can improve the 
overall effectiveness of an ECP-derived antitumor therapy. On the other hand, these tolerizing 
APCs can now be exclusively used to investigate their therapeutic potency in autoimmune 
models also. In fact, our collaborators at Northwestern University have generated preliminary 
data indicating that PUVA-exposed passaged splenocytes slow rejection in a murine cardiac 
transplant model (unpublished data).  
The benefits of this tunable system go beyond the ability to modify the original ECP 
procedure. It can also aid in further exploration of the ECP mechanism. As a result, we were 
able to establish clear mechanistic parallels with ECP by subtracting components during the 
treatment process, helping to decipher their relative contributions to the antitumor response.  
Initially, we established that the TI effect was immune mediated. This was accomplished 
by the successful transfer of the TI response to naïve untreated recipient mice via splenocytes. 
The effect was preserved with the enrichment of T cells and removal of B cells, indicating an 
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important subset of T cells may provide TI-specific memory. CD4+ T cells being a likely source 
for such memory, lead us to investigate their cytokine production in spleen transfer recipient 
mice.  We found IFN-g production that was only present when TI-specific CD11b+ APCs and 
CD4+ T cells were incubated together. This IFN-g production was significantly inhibited by 
disrupting MHCII presentation with a blocking antibody, indicating that the cytokine production 
was mediated through MHCII. Moreover, we found through in vivo depletions that CD4+ cells 
were necessary for the TI response. These data not only support an immune mediated TI effect, 
but specifically highlight the important role CD4+ T cells have to play. Investigations are 
underway to determine whether or not antigen-loaded TI passaged monocytes specifically are 
responsible for this MHCII presentation and CD4+ activation. 
Next, we investigated the importance of a major hallmark of ECP--plate passage itself. 
Removing the microplate, demonstrated that it was necessary for the in vivo antitumor 
response. This was the first in vivo indication that the microplate retained the functional 
capacity of its larger ECP sister chamber, and that indeed, the Transimmune response likely 
shared similarities with traditional ECP effects. On the other hand, we established that plate 
passaged APCs without PUVA-treated YUMM1.7 cells as a source of antigen, were not sufficient 
to induce an antitumor response. This illustrated that YUMM were an important source of 
antigen, and that APCs required plate passage and antigen loading to be effective.  
Given the parallels with ECP and the indication that a segment of antigen exposed plate 
passaged PBMCs were important, we investigated the possibility that these cells were activated 
monocytes acting as APCs. We chose CD11b as a broad myeloid marker of murine peripheral 
monocytes, although acknowledging it is also found on B cells and macrophage (38, 39). 
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Differentiating murine monocytes from macrophage was outside the scope of our study, and so 
we refer to the larger population as monocytes for simplicity. We first established that there 
was a CD11b+ segment of plate passaged PBMCs that were capable of engulfing PKH-labeled 
YUMM. Initial uptake studies demonstrated that YUMM-specific CD11b+ phagocytes were not 
B cells (data not shown). This YUMM uptake occurred regardless of plate passage, which is not 
unexpected given the reputation peripheral monocytes have as phagocytes. Nonetheless, if 
plate passaged monocytes were going to act as APCs, they would need to be capable of antigen 
uptake, which they are. We then established that the presence of these CD11b+ cells prior to 
plate passage was required for the in vivo TI antitumor response. Given the important role of 
plate passaged monocytes in vivo, we attempted to find a cytokine in vitro corollary of their 
potential activation. Elevations in MCP-1 and IL-6 were dependent on the presence of plate 
passaged monocytes and platelets. MCP-1 may be the most likely monocyte-specific cytokine 
since it is known to be produced by inflammatory monocytes and is a potent chemokine, 
attracting monocytes to sites of inflammation (37). Additionally, it has been reported by 
Weyrich and colleagues that MCP-1 is known to be produced by monocytes following activation 
via platelet anchoring through P-selectin (40,41). This is remarkably consistent with our data 
linking MCP-1 production with co-plate passage of monocytes and platelets, as well as 
Durrazo’s efforts linking human monocyte-to-DC differentiation to P-selectin anchoring of 
platelets following ECP. Further work is needed to show if MCP-1 is directly produced by plate 
passaged monocytes and if its production is dependent on P-selectin. Such a marker of TI-
specific monocyte activation would be valuable for optimizing the TI procedure without having 
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to wait for a longer mouse readout, and as a way to monitor the effectiveness of individual 
plate passage procedures in activating monocytes. 
With potential evidence of passaged monocyte activation and their presence being 
necessary for the TI effect, we moved to the heart of the ECP mechanism—platelet conversion 
of monocytes into functionally potent physiologic APCs. Although established by Durazzo and 
colleagues in vitro, evidence requiring platelet-monocyte interactions for a potent antitumor 
response had not been demonstrated in an in vivo system (8).  Here we show that passage of 
monocytes and platelets together are necessary for producing the Transimmune response. A 
result consistent with Durazzo’s mechanism involving activated platelets adhering to the device 
chamber wall and engaging passing monocytes in a P selectin-dependent interaction that 
promotes DC differentiation (8). This is the first study to demonstrate a murine solid tumor 
cellular immunotherapy that is potentially dependent on platelet-induced monocyte activation. 
If born out and applicable to human solid tumors, such a mechanism could open an entirely 
new field for creating potent physiologic APCs capable of generating significant T cell guided 
immune responses. 
To better characterize the efferent immune response following the reinfusion of the 
passaged cells, we performed a set of in vivo depletions. These experiments established that 
CD4 (as noted above), CD8 and NK cells were all required in the recipient mouse in order to 
develop a TI antitumor response. Given the importance of an intact CD8 T cell compartment in 
ECP-induced CTCL remissions, it was not surprising to find that cytotoxic and helper T cells were 
required in Transimmune (8, 10). However, the involvement of NK cells was unexpected. Their 
specific role is unclear, but it is possible that their influence could come as cytotoxic effectors 
33 
 
within the intratumoral environment. One possible mechanism might be through antibody 
mediated cell cytotoxicity (ADCC). Although the role a humoral response might play in TI 
remains unknown, the potential production of IL-6 following plate passage could point to T 
follicular helper (Tfh) cell activation of B cells (24). Preliminary intratumoral data from our 
colleagues has indicated a significant presence of immunoglobulin and NK cells within the 
tumors of TI treated mice (data not shown). Work is ongoing to further characterize this 
efferent immune response, including further analysis of the intratumoral environment. 
Study Limitations: As in any animal model, this is a controlled system that is useful in 
suggesting potential mechanisms of action and therapeutic benefits. The inability to completely 
mimic human disease limits its value in necessarily predicting all clinical-level responses. 
Additionally, it is worth noting that TI mice eventually succumb to their tumors despite an initial 
delay in tumor growth. We fell short of inducing regressions in any treated mice. Preliminary 
work by our colleagues has shown that treating with a cell line generated from an escaping 
tumor instead of YUMM1.7 fails to produce a TI response. This indicates that at least part of the 
mechanism of escape is likely inherent to the tumor antigen itself, which could involve a clonal 
selection of a less immunogenic mutant, or a shift in antigen expression by tumor cells over the 
course of therapy. Both avenues are under ongoing investigation as part of a larger effort to 
improve the TI antitumor response. Lastly, there is no reason to expect that the current 
protocol is entirely optimized. Attempts to increase antigen uptake or monocyte activation may 
help improve antitumor responses. These include but are not limited to: further activation of TI 
monocytes with adjuvant, use of antibodies for opsinization; the addition of calreticulin or 
other “eat me” signals for phagocytosis; using mutagenized YUMM for a source of neo 
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antigens; optimizing platelet layering in the flow chamber or increasing the number of plate 
passages for monocyte activation.  
Despite room for improvement, Transimmune has remarkably demonstrated the 
potential to create potent physiologic APCs through an ECP-inspired process, and to use those 
cells to induce a significant immunological response against murine melanoma. We are 
currently finding similar antitumor responses in colon, ovarian and other melanoma murine 
systems, expanding the potential application for this therapy (unpublished data). Consequently, 
there is intriguing hope for ECP-derived cellular immunotherapy to make additional impacts on 




Supplemental  Figure 1. PKH labeled YUMM 1.7 uptake by plate passaged and non-passaged 
monocytes. 
 
a, FACS plot of PKH vs CD11b following overnight incubation with or without plate passage. Data representative of 
three experiments. b, Phagocytic efficiency defined as a percentage of pkh-labeled CD11b cells in the presence of a 
constant, non-limiting amount of pkh-labeled YUMM (numerator box / denominator box). Data averaged over 3 
experiments.  




Hematocrit from treated and untreated mouse over the course of treatment. * Marks the end of the last treatment. 
Samples representative of blood from individual mouse. 
 
Supplemental Figure 3. Images representative of excised tumors after two and five treatments. 
 
Images of individual resected tumors after the second or fifth Transimmune treatment. Untreated tumor (PBS) 
collected on that same day for comparison. 





Serum collected 72 hours following treatment, pooled from five mice in either PBS or TI groups, and assayed via 
Luminex for cytokine analysis. Cytokines depicted here were the only ones that registered above the limit of 
detection. 
 
Supplemental Figure 5. Transimmune procedure 
 
Schema of Transimmune protocol. YUMM cells were PUVA treated separately, then incubated with PBMC, applied 
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